ADMA BIOLOGICS, INC.ADMAEarnings & Financial Report
Nasdaq
NextMar 31, 2026
ADMA Q3 2025 Key Financial Metrics
Revenue
$134.2M
Gross Profit
$75.6M
Operating Profit
$51.0M
Net Profit
$36.4M
Gross Margin
56.3%
Operating Margin
38.0%
Net Margin
27.1%
YoY Growth
12.0%
EPS
$0.15
Financial Flow
ADMA BIOLOGICS, INC. Q3 2025 Financial Summary
ADMA BIOLOGICS, INC. reported revenue of $134.2M for Q3 2025, with a net profit of $36.4M (27.1% margin). Cost of goods sold was $58.6M, operating expenses totaled $24.6M.
Key Financial Metrics
| Total Revenue | $134.2M |
|---|---|
| Net Profit | $36.4M |
| Gross Margin | 56.3% |
| Operating Margin | 38.0% |
| Report Period | Q3 2025 |
ADMA BIOLOGICS, INC. Annual Revenue by Year
ADMA BIOLOGICS, INC. annual revenue history includes year-by-year totals (for example, 2024 revenue was $426.5M).
| Year | Annual Revenue |
|---|---|
| 2024 | $426.5M |
| 2023 | $258.2M |
| 2022 | $154.1M |
Income Statement
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $73.9M | $81.9M | $107.2M | $119.8M | $117.5M | $114.8M | $122.0M | $134.2M |
| YoY Growth | 47.9% | 43.9% | 78.3% | 78.1% | 59.1% | 40.2% | 13.8% | 12.0% |
Balance Sheet
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $329.2M | $350.9M | $376.4M | $390.6M | $488.7M | $510.6M | $558.4M | $568.7M |
| Liabilities | $194.0M | $197.2M | $188.1M | $158.7M | $139.7M | $137.2M | $160.1M | $137.5M |
| Equity | $135.2M | $153.7M | $188.3M | $231.9M | $349.0M | $373.4M | $398.3M | $431.2M |
Cash Flow
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $17.6M | $-2.2M | $45.6M | $25.0M | $50.2M | $-19.7M | $21.1M | $13.3M |